H uman immunodeficiency virus 1 infection is associated
with numerous immunological deficiencies, several of which are related with immune hyperactivation. This immune hyperactive state has a systemic effect even on cells that are not direct targets for viral replication such as B lymphocytes. HIV-1 infection has long been recognized to cause B cell dysfunctions, including hypergammaglobulemia (1, 2), nonspecific B cell activation (1, 3) , class switching (4) , and a loss of the capacity to generate and maintain memory (5), among others (3, (6) (7) (8) (9) . The underlying mechanisms behind these dysfunctions are poorly understood, but are thought to be caused by high viral load and CD4 + T cell depletion (4, 10) . Nevertheless, some B cell abnormalities are still observed in patients undergoing successful antiretroviral therapy (10) (11) (12) (13) . Other factors may thus contribute to the major alterations of the B cell compartment.
Different cytokines and growth factors have been suggested to affect basic B cell functions because they are increased in the serum of HIV-1-infected individuals (14) (15) (16) (17) (18) (19) . The B cell-activating factor (BAFF) (20, 21 ) is one such cytokine that is mainly expressed by myeloid lineage cells (22, 23) and is a potent regulator of B cell development and functions (24) (25) (26) (27) . In animal models, overexpression of BAFF leads to B cell hyperplasia, lymphoproliferation, hypergammaglobulinemia, and symptoms of autoimmunity, thus suggesting that an increase of BAFF secretion may lead to autoreactivity (28) . Importantly, enhanced levels of BAFF are detected in several autoimmune diseases and/or chronic infections and are frequently correlated with disease progression (29) . Several groups have studied BAFF levels and B cell responses in the context of HIV-1 infection (20, 21, 24, (30) (31) (32) . For example, BAFF and Ig levels were found to be increased as HIV-1 disease progresses, therefore suggesting a role for BAFF in the hypergammaglobulinemia observed in HIV-1 infection (20, 21) . Studies on the role of dendritic cells (DCs) and derived growth factors in triggering and perpetuating B cell disorders in HIV-1-infected individuals revealed that plasma levels of BAFF, IL-6, IL-10, and cell surface expression of BAFF on myeloid DCs and monocytic precursors were elevated in the early phase of infection and remained high during the chronic phase, despite antiretroviral therapy, in both normal and rapid progressors (30) . Moreover, recombinant soluble HIV-1 gp120 external envelope (Env) glycoprotein was reported to induce production of functionally active BAFF by human monocytes (24) .
Monocytes play significant roles in innate and adaptive immunity due to their ability to differentiate into macrophages and DCs. Monocytes are secretory cells that contribute to the alteration of the cytokine/chemokine profiles during HIV-1 infection (33) . Although increased BAFF expression by human monocytes during HIV-1 infection (21, 30) or upon gp120 stimulation (24) has been reported, the exact mechanism(s) underlying this augmentation remains unclear. In this study, we investigated the ability of fully competent HIV-1 to induce BAFF production by human monocytes. We demonstrate that HIV-1 drives BAFF secretion in monocytes by a type I IFN-dependent process. Moreover, we identified plasmacytoid DCs (pDCs) as the cellular source of this type I IFN-directed modulatory effect in our monocyte cultures, demonstrating that a pDC/monocyte interplay is required for the HIV-1-induced BAFF production. Interestingly, we report that BAFF secretion shows sex-related differences because monocytes from women produce higher levels of BAFF compared with men. Finally, we demonstrate that cell-associated BAFF is present in the three monocyte subsets (based on their CD14 and CD16 expression). Although nonclassical monocytes show a higher basal production of BAFF, only classical and intermediate monocytes demonstrate an increased BAFF production upon HIV-1 exposure. Altogether our findings suggest that a pDC/monocyte crosstalk is necessary for BAFF upregulation during HIV-1 infection, which might affect normal B cell functions.
Materials and Methods

Ethics statement and cell culture
The current study was approved by the Institutional Bioethics Committee (i.e., Centre Hospitalier Universitaire de Québec-Pavillon Centre Hospitalier de l'Université Laval). Peripheral blood samples were collected from healthy donors in accordance with the guidelines of the Institutional Bioethics Committee. Monocytes were purified from Ficoll-enriched PBMCs using an immunomagnetic Easysep human monocyte enrichment kit without CD16 depletion (Stemcell Technologies, Vancouver, BC, Canada). In some experiments, pDCs were depleted from PBMCs using a CD304 positive selection MicroBead kit (Miltenyi Biotec, Auburn, CA). pDCs were also purified using a negative selection human plasmacytoid DC enrichment kit (Stemcell Technologies). Cell cultures were maintained in complete RPMI 1640 medium at 37˚C under a 5% CO 2 atmosphere. Human embryonic kidney 293T cells used for transient transfections were cultured in complete DMEM. HEK-blue IFN-a/b cells were purchased from InvivoGen (San Diego, CA) and maintained in complete DMEM culture medium supplemented with 100 mg/ml zeocin, 30 mg/ml blasticidin, and 100 mg/ml primocin (InvivoGen).
Abs and reagents
Poly(I:C) (TLR3 agonist), R837 (Imiquimod; TLR7 ligand), and QUANTIBlue reagent (alkaline phosphatase detection medium) were all purchased from InvivoGen. Human rIFN-a2a was obtained from R&D Systems (Minneapolis, MN). Recombinant soluble CD4 (sCD4), which contains the first two domains of human CD4, was provided by the National Institutes of Health AIDS Reagent Program (Germantown, MD). The B18R decoy receptor for type I IFN was purchased from Affymetrix eBioscience (San Diego, CA). The culture medium used in our experiments was RPMI 1640 (Wisent, St.-Bruno, QC, Canada) and DMEM (Life Technologies by Life Technologies, Burlington, ON, Canada) supplemented with 10% heat-inactivated FBS (Wisent) and 100 U/ml penicillin-streptomycin (Invitrogen, Burlington, ON, Canada). FITC-conjugated mouse anti-human CD303 (BDCA-2; clone AC144) was purchased from Miltenyi Biotec, and PE-conjugated mouse anti-human HLA-DR (clone G46-6) was obtained from BD Biosciences (Mississauga, ON, Canada). PE-conjugated mouse antihuman CD14 (clone 61D3) and allophycocyanin-conjugated mouse antihuman CD16 (clone CB16) were purchased from Affymetrix eBioscience (San Diego, CA). PerCP-conjugated mouse anti-human BAFF (clone 137314) was purchased from R&D Systems, whereas the soluble human BAFF matched pair detection set was obtained from Adipogen (San Diego, CA).
Viral preparations
Virus particles were produced by calcium-phosphate transfection of 293T cells, as previously described (34), using a plasmid coding for wild-type X4-tropic NL4-3 particles (pNL4-3) (35) or a plasmid coding for R5-tropic Bal Env glycoproteins inserted within the NL4-3 backbone (pNL4-3Balenv) (36) . Mock control consists of 293T cells transfected with an equimolar amount of pcDNA3.1 (control empty vector). Cell-free supernatants were ultracentrifugated to eliminate free p24, resuspended in endotoxin-free PBS (Sigma-Aldrich, Oakville, ON), and quantified by an in-house double-Ab sandwich ELISA specific for the major core p24 protein (37) .
HIV-1 incubation assays
Monocytes purified from PBMCs or monocytes purified from pDC-depleted PBMCs were incubated with NL4-3 or NL4-3Balenv (10 ng p24 per 1 3 10 5 cells), poly(I:C) (30 mg/ml), IFN-a2a (2,500 U/ml), R837 (10 mg/ml), or mock control in polypropylene tubes for 24 h at 37˚C. Purified pDCs (20,000 cells/ml) were incubated with NL4-3 or NL4-3Balenv (100 ng p24) for 24 h at 37˚C. In some experiments, the type I IFN inhibitor B18R (38-41), a vaccinia virus-derived soluble receptor that blocks the effect of biologically functional type I IFN, was added to the culture medium when initiating the experiment (at a final concentration of 100 ng/ml). In other studies, sCD4 (20 mg/ml) was added to the culture medium to block interactions between gp120 and the primary cell surface receptor CD4.
Analysis of BAFF mRNA expression and protein abundance
The total RNA was isolated from monocytes (1 3 10 6 ) using the illustra RNAspin Mini Kit (GE Healthcare, Mississauga, ON) and was reverse transcribed using Moloney murine leukemia virus enzyme (Promega, Madison, WI). Transcripts were quantified by real-time PCR using SYBR Green Master Mix on an ABI-PRISM 7500 Sequence Detector (Applied Biosystems, Carlsbad, CA). BAFF and 18S cDNAs were both amplified using the following gene-specific primers: BAFF forward (59-TGAAA-CACCAACTATACAAAAAG-39), BAFF reverse (59-TCAATTCATCCC-CAAAGACAT-39), 18S forward (59-TAGAGGGACAAGTGGCGTTC-39), and 18S reverse (59-CGCTGAGCCAGTCAGTGT-39). The relative changes in gene expression were calculated using the 2 2DDCt method (42). This method was used after validation experiments demonstrated that the efficiencies of the target and endogenous reference (i.e., 18S) were approximately equal. DNA levels were normalized by quantifying 18S gene. Results were expressed as fold increase in normalized values over that observed with mock control cells. BAFF levels were quantified in cell-free supernatants with a commercially available ELISA kit, according to the manufacturer's protocol (Adipogen). FIGURE 1. HIV-1 drives BAFF expression and secretion by human monocytes. (A) Cells were isolated from PBMCs by negative selection using magnetic beads. Immediately following cell isolation, purified monocytes were exposed for 24 h to NL4-3 and Bal. In some conditions, cells were either left untreated (mock) or treated with poly(I:C) (used as a positive control). Thereafter, total RNA was extracted and BAFF mRNA was evaluated by semiquantitative real-time PCR. Results are expressed as fold increase relative to the mock-treated control cells. Data shown represent the means 6 SEM of four different donors. Statistical analysis was made using one-way ANOVA, followed by Dunnett multiple comparisons test. Asterisks denote statistically significant data (*p , 0.05). (B) Cell-free supernatants were harvested, and BAFF protein levels were evaluated by a commercial ELISA kit. Results shown are expressed as pg/ml BAFF protein for eight different donors. Each symbol represents a different donor. The horizontal line represents the mean of all donors. Statistical analysis was made using one-way ANOVA, followed by Dunnett multiple comparisons test. Asterisks denote statistically significant data (**p , 0.01, ***p , 0.001). ns, not significant. 
Detection of type I IFN
Flow cytometry
Before staining, cells were incubated with 20% pooled human sera to block nonspecific binding sites and washed once with PBS supplemented with 0.5% BSA. Cell surface expression of BDCA-2, HLA-DR, CD14, and CD16 was monitored on monocytes by flow cytometric analysis. In brief, cells were incubated for 15 min with fluorochrome-labeled Abs and then washed twice with wash buffer (i.e., PBS [pH 7.4], 1 mM EDTA, and 0.5% BSA). Cells were fixed in 2% paraformaldehyde for 30 min at 4˚C. In some experiments, cell-associated BAFF was analyzed in different monocyte subpopulations. In brief, monocytes were treated with Golgistop (BD Biosciences) for 6 h, and cell surface staining of CD14 and CD16 was performed, as described above. After fixation and permeabilization using Cytofix/Cytoperm kit (BD Biosciences), cells were stained with anti-BAFF (5 mg) for 30 min at 4˚C and then washed twice with wash buffer. After acquisition on a FACSCanto flow cytometer (BD Biosciences), data were analyzed with FCS express 4 software (De Novo Software, Los Angeles, CA).
Statistical analysis
Means of raw data were compared using either Student t test or one-way ANOVA, followed by Dunnett/Bonferroni multiple comparisons when more than two means were considered. The p values ,0.05 were deemed statistically significant. Calculations were performed with the GraphPad PRISM 6 for Windows (GraphPad Software, La Jolla, CA).
Results
HIV-1 increases BAFF expression and secretion in human monocytes
Based on the previous report showing that recombinant soluble HIV-1 gp120 induces production of functionally active BAFF by human monocytes (24), we tested whether whole HIV-1 particles were also able to upregulate BAFF expression in primary human monocytes. As shown in Fig. 1A , BAFF mRNA levels were increased upon exposure to both NL4-3 and NL4-3Balenv (called Bal hereinafter) compared with controls (called mock hereinafter). The TLR3 agonist poly(I:C) was used as a positive control in the current studies due to its known capacity to upregulate BAFF expression in different cell types (43) (44) (45) . BAFF, as other members of the TNF superfamily, can be produced as a soluble protein (23) . Therefore, we investigated BAFF secretion in monocyte supernatants using a commercial ELISA kit. As depicted in Fig. 1B , both NL4-3 and Bal could mediate a statistically significant increase in BAFF secretion when compared with controls. The difference between NL4-3-and Bal-mediated induction of BAFF protein secretion was not statistically significant. In these experiments, IFN-a (i.e., IFN-a2a) was also used as an additional positive control due its capacity to increase BAFF secretion in human monocytes (46) .
HIV-1-induced BAFF secretion in monocytes relies on type I IFN produced by pDCs
It has been reported that BAFF levels are upregulated during inflammation and/or chronic infections (22, 47) . Previous studies ) were incubated with a 1:10 dilution of each monocyte culture supernatant. Next, cells were incubated for 16 h before adding the secreted embryonic alkaline phosphatase substrate (Quanti-blue), and secreted embryonic alkaline phosphatase activity was measured by spectrophotometry. Results are expressed as relative type I IFN activity that was calculated by dividing the OD at 655 nm for the treated cells by the OD at 655 nm for the mock-treated control cells for eight different donors. Each symbol represents a different donor. The horizontal line represents the mean of all donors. Statistical analysis was made using one-way ANOVA, followed by Dunnett multiple comparisons test. Asterisks denote statistically significant data (*p , 0.05, **p , 0.01). (B) The vaccinia virus IFNa/b decoy receptor B18R recombinant protein was added at a concentration of 100 ng/ml to cell cultures. Type I IFN biological activity from monocyte cultures was analyzed, as previously described for six different donors. Statistical analysis was made using one-way ANOVA, followed by Bonferroni multiple comparisons test. Asterisks denote statistically significant data (**p , 0.01, ****p , 0.0001). (C) Cell-free supernatants were harvested, and BAFF protein levels were evaluated by a commercial ELISA kit. Results shown are expressed as pg/ml BAFF protein for six different donors. Statistical analysis was made using one-way ANOVA, followed by Bonferroni multiple comparisons test. Asterisks denote statistically significant data (****p , 0.0001). ns, not significant. have shown also that increased BAFF levels observed in certain chronic autoimmune disorders and chronic inflammatory diseases were associated to an elevated type I IFN response (48) (49) (50) . Moreover, in vitro studies have demonstrated that viruses can induce high expression of BAFF through a type I IFN pathway in different cell types (43, 44) . Therefore, we evaluated the possible involvement of type I IFN in the virus-directed BAFF production by human monocytes. An enhancement in type I IFN production was detected in supernatants from monocytes incubated with both NL4-3 and Bal (Fig. 2A) . To more directly assess the relative contribution of type I IFN in BAFF production, additional experiments were performed with the vaccinia virus IFN-a/b decoy receptor B18R protein. The HIV-1-dependent induction of type I IFN activity and BAFF protein levels was abrogated by the soluble B18R protein (Fig. 2B, 2C, respectively) , therefore indicating that type I IFN plays a dominant role in this process. Importantly, the viability of cell cultures was unaffected by the soluble B18R protein (as monitored with the 7-aminoactinomycin D viability dye) (data not shown).
The results obtained to date suggest that BAFF secretion by primary human monocytes in response to HIV-1 depends on type I IFN production. These results are surprising because monocytes were never reported before to be strong producers of type I IFN in response to HIV-1. This type of response has instead been shown to be a hallmark of some specialized innate immune cells called blood pDCs. They constitute ∼0.1-0.5% of circulating PBMCs and specifically recognize pathogens containing ssRNA by TLR7 and unmethylated CpG DNA motif via TLR9. pDCs produce up to 1,000-fold more IFN-a than other types of blood cells in response to viruses (51, 52) . Based on this information, we monitored the overall purity of our monocyte cultures using some specific pDC markers (i.e., HLA-DR and BDCA-2). A small but significant percentage of pDCs could be reliably detected in our monocyte cultures (i.e., ∼1-2% of purified cells) (Fig. 3A) . To assess the possible contribution of pDCs in the detected type I IFN production, purified pDCs were directly incubated with NL4-3 or Bal. As shown in Fig. 3B , type I IFN levels were found to be comparable to those detected in our monocyte cultures containing pDCs ( Fig. 2A) . Next, the importance of this small number of pDCs to the virus-induced BAFF production by monocytes was studied by depleting pDCs with CD304 microbeads. Successful depletion of pDCs was assessed by HLA-DR and BDCA-2 staining of monocyte cultures (data not shown). As shown in Fig. 3C , although TLR3 stimulation with poly(I:C) triggered type I IFN production in pDC-depleted monocytes, exposure to either HIV-1 or the TLR7 agonist R837 could no longer induce the secretion of type I IFN. The lack of type I IFN secretion upon TLR7 stimulation with R837 was also an indication that our monocyte cultures were depleted of pDCs. These cell supernatants were further tested for BAFF protein levels, and, as expected, both HIV-1 and R837 were no longer able to upregulate BAFF secretion in pDC-depleted monocytes (Fig. 3D) . Therefore, it can be concluded that the HIV-1-induced type I IFN secretion by pDCs drives BAFF expression in primary human monocytes.
Virus-binding event is essential for induction of type I IFN and BAFF in monocytes
In contrast to myeloid DCs, pDCs produce high levels of IFN-a in presence of HIV-1 (53) and are thus relatively resistant to pro-FIGURE 3. Type I IFN is produced by pDCs. (A) Monocytes were isolated from PBMCs by negative selection using magnetic beads. A small fraction of cells was stained with FITC-conjugated anti-HLA-DR and PEconjugated anti-BDCA-2 Abs to estimate the proportion of pDCs in purified monocyte cultures. (B) pDCs were purified from PBMCs by negative selection using magnetic beads. Immediately following cell isolation, purified pDCs were either left untreated (mock) or treated for 24 h with NL4-3 or Bal. Quantification of type I IFN in pDC culture supernatants was achieved, as previously described. Results are expressed as relative type I IFN activity that was calculated by dividing the OD at 655 nm for the treated cells by the OD at 655 nm for the mock-treated control cells for eight donors. Each symbol represents a different donor. The horizontal line represents the mean of all donors. Statistical analysis was made using oneway ANOVA, followed by Dunnett multiple comparisons test. Asterisks denote statistically significant data (**p , 0.01). (C) Primary human monocytes were depleted of pDCs and incubated with HIV-1. In some conditions, cells were either left untreated or treated with R837 or poly(I:C). Results are expressed as relative type I IFN activity that was calculated as previously described for five donors. Each symbol represents a different donor. The horizontal line represents the mean of all donors. Statistical analysis was made using one-way ANOVA, followed by Dunnett multiple comparisons test. Asterisks denote statistically significant data (**p , 0.01). (D) BAFF protein levels were estimated by a commercial ELISA kit. In this series of investigations, cells were also treated with IFN-a (2500 U/ml). Results shown are expressed as pg/ml BAFF protein for five different donors. Statistical analysis was made using one-way ANOVA, followed by Dunnett multiple comparisons test. Asterisks denote statistically significant data (**p , 0.0, ***p , 0.001). ns, not significant. ductive infection (54) . The major pathway of IFN-a production by pDCs requires virus uptake by endocytosis, as TLR7, which recognizes the viral RNA, is located in the endosomal compartment rather than at the cell membrane (51) . Although pDCs express all cell surface receptors required for HIV-1 entry (i.e., CD4, CXCR4, and CCR5) (55), only Env-CD4 association seems to be sufficient to result in type I IFN production (53) . Consequently, we studied the putative role of Env-CD4 interaction in triggering type I IFN release and the ensuing BAFF upregulation in cultures made of monocytes and pDCs. Production of both type I IFN and BAFF was significantly inhibited in presence of sCD4 (Fig. 4, respectively) , which is known to bind to gp120 and abrogate the contact between Env and CD4. Furthermore, an absence of type I IFN and BAFF secretion was also seen when primary human monocytepDC cultures were similarly incubated with NL4-3-based Envdeficient virus (called NL4-3ΔEnv) (data not shown). Altogether these results indicate that an intimate interaction between HIV-1 Env and CD4 is mandatory to lead to type I IFN production by pDCs and the subsequent BAFF secretion by monocytes.
BAFF secretion shows sex-related differences
A careful analysis of basal levels of BAFF secretion by human monocytes highlighted considerable donor-to-donor variations (Fig. 1B, mock samples) . Given the previously reported strong gender bias in murine models of autoimmunity and the demonstrated implication of BAFF in this phenomenon (56) , additional studies were performed and data were analyzed in light of the gender factor. Data depicted in Fig. 5 indicate that samples from females secrete nearly 2-fold more basal levels of BAFF than samples from male donors. Furthermore, this 2-fold increase can be seen when using different stimuli [i.e., HIV-1, poly(I:C), and IFN-a]. However, a comparable 1.5-fold increase in BAFF secretion by male and female donor samples was seen in response to HIV-1, poly(I:C), or IFN-a treatment when compared with mocktreated cells.
Cell-associated BAFF in monocyte subsets
BAFF is a type II membrane protein of the TNF superfamily that is expressed as a membrane-bound form that can be cleaved by a furin family protease to generate its soluble form (26, 27) . Membranebound BAFF has been reported to be increased on mature DCs and monocytic precursors in HIV-1-infected patients (30) . Therefore, we analyzed cell-associated BAFF (membrane and intracellular protein) by flow cytometry in monocytes following incubation with HIV-1 (Fig. 6A) . The increase in mean fluorescence intensity was modest following each treatment, and it was not statistically significant when compared with mock control (Fig. 6A and data not shown). However, as shown in Fig. 6B , the percentages of BAFF + monocytes were increased in a statistically significant manner in presence of NL4-3 (44.3%) and Bal (57.5%) as well as following a treatment with poly(I:C) (56.3%) and IFN-a (50.0%) when compared with mock-treated cells (22.9%).
Human monocytes can be divided into classical, intermediate, and nonclassical subsets based on their differential expression of CD14 and CD16 (57) . These cell subsets display distinct physi-FIGURE 4. Env-CD4 interaction is necessary to induce type I production by pDCs and BAFF secretion by monocytes. (A) Monocytes were isolated from PBMCs without depleting pDCs. Next, monocyte cultures were either left untreated or incubated with HIV-1 either in absence or presence of sCD4. Type I IFN biological activity from culture supernatants was evaluated, as previously described. Results are expressed as relative type I IFN activity for five different donors. Statistical analysis was made using one-way ANOVA, followed by Bonferroni multiple comparisons test. Asterisks denote statistically significant data (**p , 0.01, ****p , 0.0001). (B) Using the same cell-free supernatants as in (A), BAFF protein levels were evaluated by a commercial ELISA kit. Results shown are expressed as pg/ml BAFF protein for five different donors. Statistical analysis was made using one-way ANOVA, followed by Bonferroni multiple comparisons test. Asterisks denote statistically significant data (*p , 0.05). ns, not significant. . BAFF secretion shows sex-related differences. Monocytes were isolated from PBMCs without depleting pDCs, and BAFF protein levels were evaluated by a commercial ELISA kit. Results shown are expressed as pg/ml BAFF protein for four different donors in each group. Each symbol represents a different donor. The horizontal line represents the mean of all donors. Statistical analysis was made using Student t test when means of basal BAFF secretion between males and females were compared. Asterisks denote statistically significant data (*p , 0.05). One-way ANOVA, followed by Dunnett multiple comparisons test, was used when BAFF secretion was analyzed separately between male and female donors. Male n = 4 (**p , 0.01, *p , 0.05). Female n = 4 (*p , 0.05, **p = 0.01).
ological and functional characteristics, allowing them to be involved in separate immunological pathways (58) . We thus evaluated the involvement of the different monocyte subpopulations to the virus-mediated BAFF production. Untreated and treated primary human monocytes were subdivided in three distinct subsets based on CD14 and CD16 expression, as illustrated in Fig. 6C . Although all three monocyte subpopulations were found to express BAFF endogenously (Fig. 6D) , the virus-dependent increase in BAFF production was only seen in classical (CD14 high CD16 2 ) and intermediate monocytes (CD14   high   CD16 + ) when compared with mock-treated cells. Despite the fact that nonclassical monocytes (CD14 low CD16 + ) did not upregulate BAFF expression upon exposure either to HIV-1, poly(I:C), or IFN-a, they nonetheless showed the highest basal expression levels of BAFF (mock: 47.3%) when compared with classical (mock: 17.3%; *p , 0.05) and intermediate monocytes (mock: 28.8%; **p , 0.01). Overall our results prompt us to propose a working model explaining the increased BAFF production seen in the context of HIV-1 infection (Fig. 7) .
Discussion
B cell abnormalities in the context of HIV-1 immunopathogenesis have been studied since the beginning of the pandemic and have been shown to be multifactorial. Several mechanisms have been proposed to influence the normal functionality of the B cell compartment, including a direct virus interaction with B cells or an indirect effect associated with production of soluble factors as a consequence of the chronic immune activation seen during HIV-1 infection. One of these factors, BAFF, has been postulated to contribute in a significant manner to HIV-1-associated B cell dysfunctions (20, 21, 24, 30) .
Physiological levels of BAFF must be tightly regulated because abnormal concentrations of this cytokine dramatically affect B cell functions as observed in different inflammatory and infectious diseases (47) . In the present work, we show that HIV-1 induces BAFF expression and secretion by primary human monocytes independently of viral coreceptor usage. We then proceed to characterize this phenomenon by revealing that this upregulation is driven by a type I IFN-dependent process. It is now well established that type I IFN responses represent the canonical host innate immune response to viruses, which serves to enhance expression of antiviral restriction factors and augment adaptive immune defenses (59) . Type I IFN is readily measured in peripheral blood samples from patients acutely infected with HIV-1 (60), and pDCs, not monocytes, were identified as the major human PBMC subset that was responsible for the production of type I IFN in response to HIV-1. Although pDCs represent only 0.1-0.5% of PBMCs, they can generate large amounts of type I IFN (51, 52, 59) . We analyzed the possible presence of pDCs in our purified monocyte cell cultures and a small but consistent number of pDCs was detected. By depleting pDCs from our monocyte cultures, we demonstrate that these cells were indeed the source of HIV-1-induced type I IFN necessary to promote BAFF production by monocytes. pDC-depleted monocytes were still able to produce type I IFN, as previously reported in monocytes and macrophages (61, 62) , and produce BAFF upon poly(I:C) stimulation. Importantly, although pDC expression of BAFF has been reported to be upregulated by type I IFN in some situations (63, 64) , BAFF levels in the supernatants of purified pDCs exposed to HIV-1 were always found to be near the threshold of detection or undetectable (data not shown). Production of type I IFN by pDCs in response to HIV-1 involves endocytosis of HIV-1 via an interaction between Env and CD4 and the recognition of viral genomic ssRNA by TLR7 localized in the endosomal compartment (51) . As expected, blocking HIV-1 attachment to CD4 using a recombinant sCD4 protein in pDC-monocyte cultures strongly inhibited type I IFN production by pDCs and thus abrogated BAFF production by monocytes. Altogether, these results reveal the potential importance of a pDC-monocyte crosstalk that could lead to increased BAFF levels during HIV-1 infection. He et al. (24) previously described an increased BAFF expression by monocytes in response to recombinant monomeric gp120 protein.
In this study, they showed that soluble gp120 can directly increase BAFF production by monocytes by attachment to CD4, CXCR4, or CCR5. Although it is possible that soluble gp120 or HIV-1 particles can directly bind to monocytes and drive BAFF production to a cer-FIGURE 7. Hypothetical working model to explain the elevated BAFF production in HIV-1 infection. Cell-free virions circulating in peripheral blood associate with pDCs via Env-CD4 interactions and are internalized by endocytosis. Once into the endosomal compartment, viruses are degraded and viral RNA is recognized by TLR7, which triggers pDC activation and the induction of a type I IFN response, contributing to the general state of immune activation that characterizes HIV-1 infection. Thereafter, type I IFN promotes membrane-bound BAFF production on both classical and intermediate monocytes, and soluble BAFF is subsequently released by a furin protease. The expansion of CD16 + monocytes, especially nonclassical monocytes that secrete high basal levels of BAFF, might also contribute to increased BAFF levels in peripheral blood. Higher concentrations of soluble BAFF could drive the expansion of immature/transitional B cells and support the survival of low-affinity self-reactive B cells (4, 68) . Type I IFN produced by pDCs, gp120 binding to C-type lectins that are constitutively expressed on B cells (24) , cell-free HIV-1 particles, excess production of proinflammatory cytokines such as TNF-a and IL-6, extracellular heat shock proteins (69), LPS and bacterial DNA/ cell wall possibly released into the circulation following intestinal tissue damage due to dramatic HIV-1-induced T cell depletion in the gut, as well as increased levels of BAFF among other factors can contribute to the activation of naive mature B cells and the increase of B cell turnover. High BAFF levels produced by monocytes and chronic immune activation could in turn promote T cell-independent activation of B cells, a process leading to hypergammaglobulinemia, an increased number of exhausted B cells, and a loss of memory B cells. At the same time, crosstalk between pDCs and DCs/macrophages at inflammation sites might also contribute to enhance the local concentration of BAFF, thereby affecting surrounding B cell responses. Finally, even when viral load is reduced following initiation of antiretroviral therapy, not all B cell responses are restored. The continuous activation of myeloid cells due to bacterial translocation and the persistence of chronic inflamed mucosal tissues observed in HIV-1-treated patients could sustain elevated levels of BAFF that could maintain such B cell dysfunctions. tain extent, results obtained using pDC-depleted monocyte cultures rather suggest that primary human monocytes by themselves respond poorly to HIV-1 particles and that BAFF secretion by monocytes occurs only in response to type I IFN.
Further examination of BAFF expression by monocytes upon incubation with HIV-1 in the presence of pDCs also showed a greater cell-associated BAFF induction. The HIV-1-mediated induction was significant when we analyzed the percentage of BAFF + monocytes, but not at the level of mean fluorescence intensity. This observation suggests that HIV-1 (and other treatments) increases the number of monocytes that express BAFF, but that expression levels of BAFF per cell increase only slightly or remain stable. Interestingly, cellassociated BAFF displayed a more significant fold increase upon HIV-1 exposure compared with soluble BAFF (i.e., NL4-3: p , 0.05; Bal: p , 0.01) (data not shown). This finding suggests that there might be other regulatory steps involved in the release of BAFF such as the control of a putative furin protease activity responsible for its cleavage from the membrane. It is of interest to note that, in the context of systemic lupus erythematosus, one recent study has reported that induction and mobilization of BAFF from intra-to extracellular compartments in monocytes were significantly influenced by IFN-a (65) . Additional studies are needed to shed light on this issue in the context of HIV-1 infection. The role of membraneassociated BAFF has not been clearly defined, although it might be important during close contacts with cells expressing its specific cognate receptors. Indeed, transmembrane activator and a calciummodulating cyclophilin ligand interactor (TACI) is a BAFF receptor that is not efficiently stimulated by soluble BAFF, but requires higherorder multimeric forms of BAFF that are reminiscent of membraneassociated BAFF (66) .
Interestingly, all monocyte subsets were shown to produce BAFF, although only classical (CD14 high CD16 2 ) and intermediate (CD14 high CD16 + ) monocytes were secreting higher amounts of BAFF upon HIV-1 exposure in the presence of pDCs. Surprisingly, whereas nonclassical monocytes (CD14 low CD16 ++ ) have the highest basal levels of BAFF production, they do not show an enhanced BAFF expression in response to HIV-1, poly(I:C), or IFN-a. These findings could have important implications during HIV-1 infection in which the expansion of CD16 + monocytes (intermediate and nonclassical) has been well described (67) .
Finally, basal BAFF secretion shows a clear sex-related difference in which monocytes from females produce higher basal BAFF levels than monocytes from male healthy donors. However, the fold increase of BAFF production induced by HIV-1 was the same in both genders. Thus, whereas the amplitude of BAFF secretion in response to a type I IFN response is similar, monocytes from females actually produce more of this cytokine than male monocytes. Mice studies have suggested a possible role of estrogen and IFN-a in the basal expression of BAFF (56) . Although this would be consistent with the strong gender bias observed in BAFF-driven autoimmune diseases, the role of estrogen in the basal secretion of BAFF by human monocytes remains to be determined.
In summary, our study provides a novel mechanistic explanation for the increased BAFF levels observed during HIV-1 infection. Our results suggest that the virus-induced type I IFN production by pDCs triggers BAFF secretion by classical and intermediate monocytes. As proposed in Fig. 7 , this study derives from a working hypothesis that highlights the importance of pDC/ monocyte crosstalk to drive BAFF production in the context of HIV-1 infection. A more complete understanding of BAFF upregulation in other cellular types during HIV-1 infection is mandatory because it might be relevant for the design of therapies that could help restore the normal functionality of the B cell compartment in HIV-1-infected individuals.
